Perkins Capital Management Inc Paratek Pharmaceuticals, Inc. Transaction History

Perkins Capital Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 21, 2023	SELL	$1.52 - $2.8 $48,640 - $89,600	-32,000 Reduced 70.02%	13,700 $30,000
Q4 2022 Jan 26, 2023	SELL	$1.67 - $2.51 $6,680 - $10,040	-4,000 Reduced 8.05%	45,700 $85,000
Q1 2022 Apr 20, 2022	SELL	$2.94 - $4.77 $30,870 - $50,084	-10,500 Reduced 17.44%	49,700 $148,000
Q4 2021 Feb 10, 2022	SELL	$4.07 - $5.3 $65,120 - $84,800	-16,000 Reduced 21.0%	60,200 $270,000
Q2 2021 Jul 28, 2021	BUY	$6.81 - $10.93 $2,383 - $3,825	350 Added 0.46%	76,200 $520,000
Q1 2021 Apr 28, 2021	BUY	$6.14 - $8.31 $465,719 - $630,313	75,850 New	75,850 $536,000

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Perkins Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Perkins Capital Management Inc with notifications on news.